Denali Therapeutics
DNLI
118 hedge funds and large institutions have $1.09B invested in Denali Therapeutics in 2019 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 14 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 25
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
4% more funds holding
Funds holding: 114 → 118 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.38% less ownership
Funds ownership: 74.94% → 74.56% (-0.38%)
26% less capital invested
Capital invested by funds: $1.49B → $1.09B (-$391M)
50% less call options, than puts
Call options by funds: $871K | Put options by funds: $1.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.47M |
| 2 |
CC
Casdin Capital
New York
|
+$4.78M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.7M |
| 4 |
Bank of New York Mellon
New York
|
+$2.14M |
| 5 |
Millennium Management
New York
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$11M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.53M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.63M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.5M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.15M |
DNLI Hedge Fund Activity: Q3 2019 in Review
118 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2019, worth a combined $1.09B — down 26% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DNLI positions and 14 closed out — a net gain of 4 holders — while 38 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.47M. The largest seller was Lord, Abbett & Co, cutting an estimated $11M.
- 118 institutional investors held Denali Therapeutics (DNLI) as of Q3 2019, up from 114 in Q2 2019.
- Funds reported $1.09B of Denali Therapeutics stock for Q3 2019, down 26% quarter-over-quarter.
- 18 funds opened new Denali Therapeutics positions in Q3 2019 and 14 closed out, a net change of +4 holders.
- The largest Denali Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $5.47M added.
- The largest Denali Therapeutics seller in Q3 2019 was Lord, Abbett & Co, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2019.